Explore our insights on various topics to stay informed and engaged.
From Stored to Defensible: What Makes Clinical Data Reliable?
A file exists, the dataset is complete, the spreadsheet can be opened. The approval email is still in the inbox.
At first glance, everything appears to be there.
But in a regulated environment, having the record is not the same as being able to defend it.
Too Early for GxP? The Costly Assumption Many Biotechs Make
“We are too early for a GxP system.”
It is a sentence many early-stage biotech companies say with good reason. The team is small. The science is still evolving. Capital is limited. Internal processes need to remain flexible. A shared drive, spreadsheets, CRO portals and email approvals can feel sufficient for the current stage.
The problem is…
A Real-World Case: The Investors Didn’t Question the Science
The science was strong. The Phase I study was progressing well. The management team believed they were ready.
A biotech startup with 18 employees was preparing for its first major investor due diligence round. But…
From Stored to Defensible: What Makes Clinical Data Reliable?
A file exists, the dataset is complete, the spreadsheet can be opened. The approval email is still in the inbox.
At first glance, everything appears
Too Early for GxP? The Costly Assumption Many Biotechs Make
“We are too early for a GxP system.”
It is a sentence many early-stage biotech companies say with good reason. The team is small.
A Real-World Case: The Investors Didn’t Question the Science
The science was strong. The Phase I study was progressing well. The management team believed they were ready.
A biotech startup with 18 employees was